Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Mar;65(3):359–364. doi: 10.1038/bjc.1992.73

In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity.

R M Phillips 1, P B Hulbert 1, M C Bibby 1, N R Sleigh 1, J A Double 1
PMCID: PMC1977599  PMID: 1558788

Abstract

The novel indoloquinone compound EO-9 is shortly to undergo phase I clinical evaluation as a potential bioreductive drug. Preclinical studies have shown that EO-9 has greater activity against cells derived from human solid tumours than leukaemias in vitro. The results of this study extend the preclinical data available on EO-9 by demonstrating that EO-9 induces a broad spectrum of activity (IC50 values range from 8 to 590 ng ml-1) against a panel of human and murine tumour cell lines. Some evidence exists of selectivity towards leukaemia and human colon cell lines as opposed to murine colon cells. The response of cells to Mitomycin C were not comparable to EO-9 suggesting that the mechanism of action of these compounds is different. The cytotoxic properties of EO-9 under aerobic conditions are significantly influenced by extracellular pH. Reduction of pH from 7.4 to 5.8 increases cell kill from 40% to 95% in DLD-1 cells. In addition, EO-9 is unstable at acidic pH (T1/2 = 37 min at pH 5.5) compared to neutral pH T1/2 = 6.3 h). The major breakdown product in vitro was identified as EO-5A which proved relatively inactive compared to EO-9 (IC50 = 50 and 0.6 ug ml-1 respectively). These studies suggest that if EO-9 can be delivered to regions of low pH within solid tumours, a therapeutic advantage may be obtained.

Full text

PDF
359

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Binger M., Workman P. Gradient high-performance liquid chromatographic assay for the determination of the novel indoloquinone antitumour agent E09 in biological specimens. J Chromatogr. 1990 Nov 16;532(2):321–336. doi: 10.1016/s0378-4347(00)83782-2. [DOI] [PubMed] [Google Scholar]
  2. Dexter D. L., Barbosa J. A., Calabresi P. N,N-dimethylformamide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res. 1979 Mar;39(3):1020–1025. [PubMed] [Google Scholar]
  3. Gutierrez P. L. Mechanism(s) of bioreductive activation. The example of diaziquone (AZQ). Free Radic Biol Med. 1989;6(4):405–445. doi: 10.1016/0891-5849(89)90087-7. [DOI] [PubMed] [Google Scholar]
  4. Jabbar S. A., Twentyman P. R., Watson J. V. The MTT assay underestimates the growth inhibitory effects of interferons. Br J Cancer. 1989 Oct;60(4):523–528. doi: 10.1038/bjc.1989.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kennedy K. A., McGurl J. D., Leondaridis L., Alabaster O. pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells. Cancer Res. 1985 Aug;45(8):3541–3547. [PubMed] [Google Scholar]
  6. King C. L., Wong S. K., Loo T. L. Alkylation of DNA by the new anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone (AZQ). Eur J Cancer Clin Oncol. 1984 Feb;20(2):261–264. doi: 10.1016/0277-5379(84)90193-7. [DOI] [PubMed] [Google Scholar]
  7. Lin A. J., Cosby L. A., Shansky C. W., Sartorelli A. C. Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. J Med Chem. 1972 Dec;15(12):1247–1252. doi: 10.1021/jm00282a011. [DOI] [PubMed] [Google Scholar]
  8. Linford J. H. 2,3,5-Tris-ethylenimino-1,4-benzoquinone (Trenimon): some chemical and biological properties. Chem Biol Interact. 1973 Mar;6(3):149–168. doi: 10.1016/0009-2797(73)90068-9. [DOI] [PubMed] [Google Scholar]
  9. Lozzio C. B., Lozzio B. B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975 Mar;45(3):321–334. [PubMed] [Google Scholar]
  10. Mossoba M. M., Alizadeh M., Gutierrez P. L. Mechanism for the reductive activation of diaziquone. J Pharm Sci. 1985 Dec;74(12):1249–1254. doi: 10.1002/jps.2600741202. [DOI] [PubMed] [Google Scholar]
  11. Orlemans E. O., Verboom W., Scheltinga M. W., Reinhoudt D. N., Lelieveld P., Fiebig H. H., Winterhalter B. R., Double J. A., Bibby M. C. Synthesis, mechanism of action, and biological evaluation of mitosenes. J Med Chem. 1989 Jul;32(7):1612–1620. doi: 10.1021/jm00127a035. [DOI] [PubMed] [Google Scholar]
  12. Phillips R. M., Bibby M. C., Double J. A. A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst. 1990 Sep 19;82(18):1457–1468. doi: 10.1093/jnci/82.18.1457. [DOI] [PubMed] [Google Scholar]
  13. Phillips R. M., Bibby M. C., Double J. A. Experimental correlations of in vitro drug sensitivity with in vivo responses to ThioTEPA in a panel of murine colon tumours. Cancer Chemother Pharmacol. 1988;21(2):168–172. doi: 10.1007/BF00257366. [DOI] [PubMed] [Google Scholar]
  14. Roed H., Aabo K., Vindeløv L., Spang-Thomsen M., Christensen I. B., Hansen H. H. In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1197–1201. doi: 10.1016/0277-5379(89)90415-x. [DOI] [PubMed] [Google Scholar]
  15. Siegel D., Gibson N. W., Preusch P. C., Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 1990 Dec 1;50(23):7483–7489. [PubMed] [Google Scholar]
  16. Soule H. D., Vazguez J., Long A., Albert S., Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973 Nov;51(5):1409–1416. doi: 10.1093/jnci/51.5.1409. [DOI] [PubMed] [Google Scholar]
  17. Tannock I. F., Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989 Aug 15;49(16):4373–4384. [PubMed] [Google Scholar]
  18. Tompkins W. A., Watrach A. M., Schmale J. D., Schultz R. M., Harris J. A. Cultural and antigenic properties of newly established cell strains derived from adenocarcinomas of the human colon and rectum. J Natl Cancer Inst. 1974 Apr;52(4):1101–1110. doi: 10.1093/jnci/52.4.1101. [DOI] [PubMed] [Google Scholar]
  19. Warner N. L., Moore M. A., Metcalf D. A transplantable myelomonocytic leukemia in BALB-c mice: cytology, karyotype, and muramidase content. J Natl Cancer Inst. 1969 Oct;43(4):963–982. [PubMed] [Google Scholar]
  20. Wike-Hooley J. L., Haveman J., Reinhold H. S. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol. 1984 Dec;2(4):343–366. doi: 10.1016/s0167-8140(84)80077-8. [DOI] [PubMed] [Google Scholar]
  21. Workman P., Walton M. I., Powis G., Schlager J. J. DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? Br J Cancer. 1989 Nov;60(5):800–803. doi: 10.1038/bjc.1989.364. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES